Predicting Dysglycemia in Individuals With Gestational Diabetes Immediately Postpartum Using Continuous Glucose Monitoring

Launched by UNIVERSITY OF MANITOBA · Jul 12, 2021

Keywords

ClinConnect Summary

This clinical trial is studying how continuous glucose monitoring (a device that tracks blood sugar levels) can help predict the risk of high blood sugar (dysglycemia) in women who have had gestational diabetes immediately after giving birth. Gestational diabetes is a condition that can occur during pregnancy and may increase the chances of developing diabetes later on. Many women do not get tested for high blood sugar after their pregnancy, even though it’s important for their health. The researchers want to see if using this monitoring device right after delivery can improve screening and help manage health risks.

To join the study, participants need to be at least 18 years old and have been diagnosed with gestational diabetes during their pregnancy. They also need to have specific health conditions, such as high blood sugar levels or a certain body weight. Participants will be asked to use a glucose monitoring device and complete some questionnaires online, and they should be comfortable communicating in English or French. This trial is currently recruiting participants, and it aims to improve awareness and management of blood sugar levels after pregnancy for better long-term health outcomes.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Pregnant individuals age 18 and older
• • Diagnosed with gestational diabetes by the Diabetes Canada guidelines (including both the preferred or alternate testing approaches) or have an HbA1c of 6.0-6.4% during pregnancy
• • Have any of the following: have an elevated fasting glucose (≥ 5.3 mmol/L) on the diagnostic 75g OGTT in pregnancy; required insulin or metformin for treatment during pregnancy; body mass index (BMI) ≥ 25kg/m2, yes/no (\<27 weeks gestation BMI of ≥25 kg/m2 or ≥27 weeks gestation predicted BMI of ≥ 25 kg/m2 using (current weight in kg - 10kg)/height in meters2)
• • Planned in-hospital delivery
• • Able to provide informed consent
• • Willingness to use the study device and complete assessments
• • Have access to email in order to complete participant questionnaire through REDCap
• Exclusion Criteria:
• • Non-gestational diabetes (i.e. pre-existing diabetes)
• • Planned x-ray, MRI or CT within 3 weeks postpartum
• • Has an implantable medical device (ex. pacemaker)
• • On medications known to affect glucose metabolism (for example glucocorticoids, metformin etc.)
• • On medications which may interfere with the Freestyle Libre 2 accuracy (for example Vitamin C \>1000mg/day)
• • Unable to speak and understand French or English
• • Unable to consent or declined informed consent